Skip to Content
Merck
All Photos(1)

Key Documents

1379401

USP

Meloxicam

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C14H13N3O4S2
CAS Number:
71125-38-7
Molecular Weight:
351.40
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

meloxicam

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

InChI

1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,19H,1-2H3,(H,15,16)/b13-11+

InChI key

DWMREKMVXIFPFM-ACCUITESSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Meloxicam USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Meloxicam Oral Suspension
  • Meloxicam Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1379423

Meloxicam Related Compound B, United States Pharmacopeia (USP) Reference Standard

1379412

Meloxicam Related Compound A, United States Pharmacopeia (USP) Reference Standard

1379445

Meloxicam Related Compound D, United States Pharmacopeia (USP) Reference Standard

1379434

Meloxicam Related Compound C, United States Pharmacopeia (USP) Reference Standard

Y0001037

Meloxicam impurity C, European Pharmacopoeia (EP) Reference Standard

Y0001036

Meloxicam impurity B, European Pharmacopoeia (EP) Reference Standard

Y0001035

Meloxicam impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001080

Meloxicam, European Pharmacopoeia (EP) Reference Standard

Y0001039

Meloxicam impurity D, European Pharmacopoeia (EP) Reference Standard

1379456

(Z)-N′-Methylmeloxicam, United States Pharmacopeia (USP) Reference Standard

BP629

Meloxicam, British Pharmacopoeia (BP) Reference Standard

PHR2501

Meloxicam Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2131

Meloxicam Impurity D

PHR2327

Meloxicam Impurity C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2500

Meloxicam Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2502

Meloxicam Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2503

Meloxicam Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R Andrew Moore et al.
The Cochrane database of systematic reviews, (4)(4), CD007552-CD007552 (2009-10-13)
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) used mainly in treating pain associated with arthritis. The usual oral dose for osteoarthritis is 15 mg daily, but lower doses of 7.5 mg are advised in older patients. This review sought to
[Meloxicam: intramuscular administration in rheumatology].
E S Tsvetkova
Terapevticheskii arkhiv, 75(8), 96-97 (2003-10-03)
Roy Fleischmann et al.
Expert opinion on pharmacotherapy, 3(10), 1501-1512 (2002-10-22)
Meloxicam (Mobic trade mark, Boehringer Ingelheim) is a relatively new oral non-steroidal anti-inflammatory drug (NSAID) approved for the treatment of osteoarthritis in the US. It has also been evaluated for the treatment of rheumatoid arthritis, ankylosing spondylitis and acute 'rheumatic'
Keiko Ogino et al.
Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 120(6), 391-397 (2003-01-17)
Meloxicam (Mobic) is a new nonsteroidal anti-inflammatory drug (NSAID) derived from enolic acid, exhibiting selectivity for cyclooxygenase (COX)-2 over COX-1. Meloxicam has shown potent anti-inflammatory and analgesic activity together with low gastrointestinal toxicity in animal models. It is a potent
Shunsuke Hamada et al.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 35(5), 4561-4566 (2014-01-07)
This study aimed to determine the prevalence of β-catenin nuclear positivity as a prognostic factor in patients with desmoid tumors (DTs) treated with meloxicam, a cyclooxygenase-2 (COX-2) selective inhibitor. Between 2003 and 2012, consecutive 31 patients with extraabdominal, sporadic DTs
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service